Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Time to Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $45.49, but opened at $48.89. Nanobiotix shares last traded at $48.6450, with a volume of 18,740 shares traded.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. TD Cowen reissued a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday, April 21st. Guggenheim increased their target price on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. Finally, UBS Group increased their price objective on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $26.67.

Nanobiotix Stock Performance

The company has a 50 day moving average price of $32.58 and a 200 day moving average price of $25.53.

Nanobiotix (NASDAQ:NBTX) last released its earnings results on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $3.42 million during the quarter. As a group, sell-side analysts anticipate that Nanobiotix S.A. – Sponsored ADR will post 0.53 earnings per share for the current year.

Hedge Funds Weigh In On Nanobiotix

Several large investors have recently added to or reduced their stakes in NBTX. Royal Bank of Canada boosted its holdings in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the period. Optiver Holding B.V. bought a new stake in Nanobiotix in the third quarter valued at $101,000. Marshall Wace LLP bought a new stake in Nanobiotix in the fourth quarter valued at $220,000. Finally, Millennium Management LLC bought a new stake in Nanobiotix in the fourth quarter valued at $390,000. 38.81% of the stock is currently owned by institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.